DVA expanded access to medicinal cannabis for veterans. Then it tightened the criteria. For veterans managing PTSD and chronic pain who had structured their treatment around that access, the change wasn’t administrative — it removed a treatment that was working.
What changed
DVA’s coverage through the Repatriation Pharmaceutical Benefits Scheme underwent a restriction of approved products and prescribing conditions. The timing was not preceded by significant public consultation with veterans or advocacy organisations.
Who it affected
Veterans using medicinal cannabis for PTSD, chronic pain, and sleep disorders related to service conditions were the primary affected group. Many had switched after conventional pharmaceutical options produced unacceptable side effects. The restriction meant either returning to those medications, absorbing full out-of-pocket costs, or going without.
The accountability gap
DVA has not published a breakdown of how many veterans were affected, what clinical evidence supported removing specific products, or what outcomes have been for affected veterans since. A department that restricts treatment for injured veterans carries an obligation to publish that data. It hasn’t.
Sources: DVA Repatriation Pharmaceutical Benefits documentation, TGA scheduling notices, veteran advocacy reporting.